Literature DB >> 33756227

The role of immune semaphorins in the pathogenesis of multiple sclerosis: Potential therapeutic targets.

Ramin Lotfi1, Rasoul Nasiri Kalmarzi2, Misagh Rajabinejad3, Sabah Hasani2, Fatemeh Zamani4.   

Abstract

The immune and nervous systems possess a highly intricate network of synaptic connections, shared messenger molecules, and exquisite communication ways, allowing intercellular signal transduction. The semaphorins (Semas) were initially identified as axonal guidance molecules in the development of the nervous system but later were found to be implicated also in regulating the immune system, known in this case as the "immune Semas" or "immunoregulatory Semas". Increasingly, these molecules are involved in multiple aspects of both physiological and pathological immune responses and were recently indicated to take part in various immunological disorders, encompassing allergy, cancer, and autoimmunity. Semas transduce signals by connecting to their cognate receptors, namely, plexins and neuropilins. Some of them, like Sema-3F, have been found to function as the inducer of the remyelination process whereas some others, like Sema-3A and Sema-4D, act to inhibit this process, either directly or indirectly. Besides, Sema-4A is crucial to the differentiation of T helper type 1 (Th1) and Th17 cells that are potentially involved in the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. This review aims to reveal the role of immune Semas in the pathogenesis of MS and its animal model, experimental autoimmune encephalomyelitis, focusing on the therapeutic usages of these molecules to treat this neurodegenerative disease.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Multiple sclerosis; Neurodegenerative disease; Neuropilins; Plexins

Mesh:

Substances:

Year:  2021        PMID: 33756227     DOI: 10.1016/j.intimp.2021.107556

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

Review 1.  Semaphorin-3A: a promising therapeutic tool in allergic rhinitis.

Authors:  Ramin Lotfi; Nahid Zamanimehr
Journal:  Immunol Res       Date:  2022-01-14       Impact factor: 2.829

Review 2.  Therapeutic applications of toll-like receptors (TLRs) agonists in AML.

Authors:  Ye Peng; Yanzhong Wang; Manling Wang; Jianping Lan; Yirui Chen
Journal:  Clin Transl Oncol       Date:  2022-08-13       Impact factor: 3.340

Review 3.  Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective.

Authors:  Alireza Kashefizadeh; Hossein Kazemizadeh
Journal:  Clin Transl Oncol       Date:  2022-09-30       Impact factor: 3.340

Review 4.  The role of NLRP3 inflammasome in colorectal cancer: potential therapeutic target.

Authors:  Somayeh Vafaei; Hamed Taheri; Yasamin Hajimomeni; Amirhossein Fakhre Yaseri; Firoozeh Abolhasani Zadeh
Journal:  Clin Transl Oncol       Date:  2022-06-10       Impact factor: 3.340

Review 5.  Role of RGC-32 in multiple sclerosis and neuroinflammation - few answers and many questions.

Authors:  Alexandru Tatomir; Jacob Cuevas; Tudor C Badea; Dafin F Muresanu; Violeta Rus; Horea Rus
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

Review 6.  Modelling and Refining Neuronal Circuits with Guidance Cues: Involvement of Semaphorins.

Authors:  Greta Limoni
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.